Mifepristone

Generic Name
Mifepristone
Brand Names
Korlym, Mifegymiso
Drug Type
Small Molecule
Chemical Formula
C29H35NO2
CAS Number
84371-65-3
Unique Ingredient Identifier
320T6RNW1F
Background

Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary c...

Indication

For the medical termination of intrauterine pregnancy through 49 days' pregnancy. Also indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and are not candidates for surgery or have had unsuccessful surgery.

Associated Conditions
Hyperglycemia
Associated Therapies
Medically induced abortion
Clinical Trials
Related News

Preliminary Trial of the Effect of Glucocorticoid Receptor Antagonist on Borderline Personality Disorder (BPD)

First Posted Date
2010-09-30
Last Posted Date
2019-02-26
Lead Sponsor
Indiana University
Target Recruit Count
22
Registration Number
NCT01212588
Locations
🇺🇸

Larue D Carter Memorial Hospital, Indianapolis, Indiana, United States

Preoperative Testing of the Anti-Progesterone Mifepristone in Early Stage Breast Cancer

Early Phase 1
Terminated
Conditions
Invasive Breast Cancer
Ductal Carcinoma in Situ
Interventions
Drug: Mifepristone
First Posted Date
2010-06-07
Last Posted Date
2019-07-08
Lead Sponsor
University of California, San Diego
Target Recruit Count
4
Registration Number
NCT01138553
Locations
🇺🇸

Moores UCSD Cancer Center, La Jolla, California, United States

Investigation of Mifepristone (RU486) on Stress Sensitivity and Relapse Prevention in Cocaine Dependent Patients

Phase 2
Completed
Conditions
Cocaine Dependence
Interventions
Drug: placebo
Drug: Mifepristone
First Posted Date
2010-05-31
Last Posted Date
2018-12-20
Lead Sponsor
New York State Psychiatric Institute
Target Recruit Count
58
Registration Number
NCT01134198
Locations
🇺🇸

STARS, New York, New York, United States

Uptake and Acceptability of Home-use of Mifepristone for Medical Abortion

Not Applicable
Completed
Conditions
Termination of Pregnancy
Interventions
Drug: Mifepristone
First Posted Date
2009-10-14
Last Posted Date
2012-04-17
Lead Sponsor
Gynuity Health Projects
Target Recruit Count
615
Registration Number
NCT00994734
Locations
🇲🇩

Municipal Clinical Hospital, Chisinau, Moldova, Republic of

🇳🇵

Kathmandu Medical College, Kathmandu, Nepal

🇳🇵

Nepal Medical College Teaching Hospital, Kathmandu, Nepal

and more 4 locations

An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome

Phase 3
Completed
Conditions
Cushing's Syndrome
Interventions
Drug: mifepristone
First Posted Date
2009-07-10
Last Posted Date
2014-04-02
Lead Sponsor
Corcept Therapeutics
Target Recruit Count
30
Registration Number
NCT00936741
Locations
🇺🇸

Cleveland Clinic Foundation; Dept of Endocrinology, Diabetes & Metabolism, Cleveland, Ohio, United States

🇺🇸

The Center for Diabetes and Endocrine Care, Hollywood, Florida, United States

🇺🇸

AMCR Institute Inc., Escondido, California, United States

and more 12 locations

Mifepristone 10 or 5 mg for 6 Months to Treat Uterine Fibroids

Phase 2
Completed
Conditions
Uterine Fibroids
Interventions
Drug: Mifepristone
First Posted Date
2009-04-23
Last Posted Date
2014-10-17
Lead Sponsor
Mediterranea Medica S. L.
Target Recruit Count
100
Registration Number
NCT00886873
Locations
🇨🇺

Hospital Eusebio Hernandez, Ciudad Habana, La Habana, Cuba

Trial of Mifepristone in Combat Veterans With Posttraumatic Stress Disorder

First Posted Date
2009-02-02
Last Posted Date
2015-04-01
Lead Sponsor
James J. Peters Veterans Affairs Medical Center
Target Recruit Count
80
Registration Number
NCT00833339
Locations
🇺🇸

James J. Peters VA Medical Center, Bronx, New York, United States

Compassionate Use of Mifepristone in Brain/Nervous System and Other Cancers

Not Applicable
Terminated
Conditions
Cancer
Interventions
Drug: Mifepristone
First Posted Date
2009-01-30
Last Posted Date
2018-06-29
Lead Sponsor
New Mexico Cancer Care Alliance
Target Recruit Count
4
Registration Number
NCT00832871
Locations
🇺🇸

Universtiy of New Mexico - Cancer Center, Albuquerque, New Mexico, United States

Treatment of Schizoaffective Disorder Using Mifepristone

First Posted Date
2008-07-30
Last Posted Date
2017-03-24
Lead Sponsor
Stanford University
Target Recruit Count
12
Registration Number
NCT00725270
Locations
🇺🇸

Stanford University School of Medicine, Stanford, California, United States

Glucocorticoid Receptor Antagonism in Subclinical Cushings

Phase 1
Completed
Conditions
Subclinical Cushing's
First Posted Date
2008-07-23
Last Posted Date
2021-01-26
Lead Sponsor
Sheffield Teaching Hospitals NHS Foundation Trust
Target Recruit Count
6
Registration Number
NCT00721201
Locations
🇬🇧

Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy